Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 4;3(2):e59.
doi: 10.1038/nutd.2013.1.

The origin of circulating CD36 in type 2 diabetes

M J Alkhatatbeh  1 , A K Enjeti, S Acharya, R F Thorne, L F Lincz
Affiliations

The origin of circulating CD36 in type 2 diabetes

M J Alkhatatbeh et al. Nutr Diabetes. .

Abstract

Objective: Elevated plasma levels of the fatty acid transporter, CD36, have been shown to constitute a novel biomarker for type 2 diabetes mellitus (T2DM). We recently reported such circulating CD36 to be entirely associated with cellular microparticles (MPs) and aim here to determine the absolute levels and cellular origin(s) of these CD36+MPs in persons with T2DM.

Design: An ex vivo case-control study was conducted using plasma samples from 33 obese individuals with T2DM (body mass index (BMI)=39.9±6.4 kg m(-2); age=57±9 years; 18 male:15 female) and age- and gender-matched lean and obese non-T2DM controls (BMI=23.6±1.8 kg m(-2) and 33.5±5.9 kg m(-2), respectively). Flow cytometry was used to analyse surface expression of CD36 together with tissue-specific markers: CD41, CD235a, CD14, CD105 and phosphatidyl serine on plasma MPs. An enzyme-linked immunosorbent assay was used to quantify absolute CD36 protein concentrations.

Results: CD36+MP levels were significantly higher in obese people with T2DM (P<0.00001) and were primarily derived from erythrocytes (CD235a+=35.8±14.6%); although this did not correlate with haemoglobin A(1c). By contrast, the main source of CD36+MPs in non-T2DM individuals was endothelial cells (CD105+=40.9±8.3% and 33.9±8.3% for lean and obese controls, respectively). Across the entire cohort, plasma CD36 protein concentration varied from undetectable to 22.9 μg ml(-1) and was positively correlated with CD36+MPs measured by flow cytometry (P=0.0006) but only weakly associated with the distribution of controls and T2DM (P=0.021). Multivariate analysis confirmed that plasma CD36+MP levels were a much better biomarker for diabetes than CD36 protein concentration (P=0.009 vs P=0.398, respectively).

Conclusions: Both the levels and cellular profile of CD36+MPs differ in T2DM compared with controls, suggesting that these specific vesicles could represent distinct biological vectors contributing to the pathology of the disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Levels of MP subsets in lean controls, obese controls and obese T2DM individuals. Data expressed as medians with bars indicating interquartile ranges. *P<0.05, **P<0.001, ***P<0.00001 vs obese controls.
Figure 2
Figure 2
Percentage of CD36+MP derived from specific MP subsets in lean controls, obese controls and obese T2DM individuals. Data expressed as mean and s.ds. +P<0.05, ++P<0.01 vs lean controls; **P<0.001, ***P<0.00001 vs obese controls.
Figure 3
Figure 3
Scatter plots of HbA1c plasma concentrations vs erythrocyte-derived MPs in obese T2DM individuals. (a) Ln Total CD235a+MPs; (b) percentage of CD36+/CD235a+MPs.
Figure 4
Figure 4
Plasma levels of CD36 protein measured by ELISA in lean controls, obese controls and obese T2DM individuals. Data expressed as median, interquartile range (boxes), upper and lower adjacent values (whiskers) and individual outliers (circles). *P<0.05 compared with obese controls.
Figure 5
Figure 5
Quartiles of plasma CD36 protein concentration measured by ELISA compared with numbers of circulating CD36+MPs measured by flow cytometry in lean controls, obese controls and obese T2DM individuals.
See this image and copyright information in PMC

References

    1. Thorne RF, Mhaidat NM, Ralston KJ, Burns GF. CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. FEBS Lett. 2007;581:1227–1232. - PubMed
    1. Silverstein RL. Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve Clin J Med. 2009;76 (Suppl 2:S27–S30. - PMC - PubMed
    1. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108:785–791. - PMC - PubMed
    1. Susztak K, Ciccone E, McCue P, Sharma K, Bottinger EP. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2005;2:e45. - PMC - PubMed
    1. Handberg A, Levin K, Hojlund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation. 2006;114:1169–1176. - PubMed